The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping
Launched by UNIVERSITY OF DUNDEE · Dec 29, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The BRIDGE Study is a research project focused on understanding bronchiectasis, a condition where the airways in the lungs become damaged and enlarged, making it hard to breathe. This study aims to identify different types of bronchiectasis by looking at patients' genetic and biological profiles. By doing so, the researchers hope to develop personalized treatment strategies that can help patients respond better to their care. The study will gather information about patients when they are stable and during flare-ups, which will help link specific patient characteristics to health outcomes.
To participate in this study, individuals must be adults aged 18 and older with a confirmed diagnosis of bronchiectasis, supported by a CT scan. Participants should have been stable for at least four weeks without needing antibiotics or steroids for their condition. Those who are eligible will be closely monitored and asked to provide information about their health, which will help researchers gain insights into the best ways to treat bronchiectasis in different patient groups. This study is currently recruiting participants, and both men and women are welcome to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A previous CT scan showing bronchiectasis along with compatible clinical syndrome of cough, sputum production and/or recurrent respiratory tract infections.
- • A primary diagnosis of bronchiectasis made by a respiratory physician
- • At the screening visit the individual will have been clinically stable for 4 weeks indicated by the lack of any treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks.
- Exclusion Criteria:
- • Inability to give informed consent
- • \<18years of age
- • Patients with active tuberculosis
- • Treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks
- • Bronchiectasis due to cystic fibrosis
About University Of Dundee
The University of Dundee is a leading research institution in the United Kingdom, renowned for its commitment to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in biomedical sciences, medicine, and health technology to address pressing health challenges. The University of Dundee fosters an environment of academic excellence, driving the development of novel therapies and interventions that aim to improve patient outcomes. Its state-of-the-art facilities and dedication to ethical research practices ensure the highest standards of clinical trial management and oversight.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dundee, , United Kingdom
Patients applied
Trial Officials
James D Chalmers, MD, PhD
Principal Investigator
GSK/British Lung Foundation Chair of Respiratory Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials